AOTI Receives China FDA Approval for Topical Wound Oxygen (TWO2) Therapy Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population
OCEANSIDE, Calif., March 23, 2022 /PRNewswire/ -- Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly...
Announcing Key Leadership Team Additions and Scientific Clinical Advisory Board Formation
OCEANSIDE, Calif., Feb. 14, 2022 /PRNewswire/ -- Advanced Oxygen Therapy Inc. (AOTI), the leader in noninvasive sustained wound healing solutions, announced today a number of significant additions to its Leadership Team, bringing to the company over 100 years of...
Durable Healing Outcomes of Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading International Clinical Conferences
OCEANSIDE, Calif., Aug. 26, 2021 /PRNewswire/ -- Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United...
2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds.
Dr. Mike Griffiths, President and CEO of Advanced Oxygen Therapy, Inc makes the cover of Healthcare Insights.
The cover story, “Advanced Oxygen Therapy, Inc: Dedicated To Resolving Acute And Chronic Wounds Through Its Unique Multi-Modality Two2 therapy,” details the company’s mission as it fights to help patients with chronic wounds.
Advanced Oxygen Therapy Inc. Named Among the 10 Most Innovative MedTech Solution Providers to Watch in 2021
AOTI announced today that it had been named among the 10 Most Innovative MedTech Solution Providers to Watch in 2021 by the journal The Healthcare Insights and is highlighted as the cover story of its May 2021 print edition.
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds.
Maintain Continuity-of-Care During the COVID-19 Pandemic
HELPING MAINTAIN CONTINUITY-OF-CARE DURING THE COVID-19 PANDEMIC TWO2 MULTI-MODALITY TOPICAL WOUND OXYGEN THERAPY PROVIDES PROVEN HEALING & WOUND PROTECTIVE CARE SAFELY FOR YOUR PATIENTS AT HOME (1) (2) (3)(1) Diabetes Care 2020; 43:616-624 (2) Vascular and...
Topical Wound Oxygen (TWO2) therapy Treats High-Risk Patients Safely at Home during the COVID-19 Pandemic
AOTI Inc. announced today that since the outbreak of the COVID-19 pandemic it has been focusing all its resources on supporting a growing number of wound care patients being treated at home by its unique multi-modality Topical Wound Oxygen (TWO2) therapy.